313 related articles for article (PubMed ID: 31925868)
1. Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis.
Aggarwal P
Dermatol Ther; 2020 Mar; 33(2):e13221. PubMed ID: 31925868
[TBL] [Abstract][Full Text] [Related]
2. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
3. Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database.
Hillen JB; Stanford T; Ward M; Roughead EE; Kalisch Ellett L; Pratt N
Drugs Real World Outcomes; 2022 Dec; 9(4):639-647. PubMed ID: 35933497
[TBL] [Abstract][Full Text] [Related]
4. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
Caldito NG; Shirani A; Salter A; Stuve O
Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
Nicholls C; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
[TBL] [Abstract][Full Text] [Related]
6. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
7. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
9. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
10. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
[TBL] [Abstract][Full Text] [Related]
11. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
13. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
14. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
[TBL] [Abstract][Full Text] [Related]
16. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
17. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
Sato K; Mano T; Iwata A; Toda T
Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
[TBL] [Abstract][Full Text] [Related]
19. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
20. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]